M3 Biotechnology, a Seattle, WA-based therapeutics company, raised $1.4m in a second funding round.
Backers included Dolby Family Ventures and the Alzheimer’s Drug Discovery Foundation (ADDF).
The company, which has raised $14M in total financing to date, will use the funds to support the launch of human trials.
Led by Leen Kawas, CEO, M3 is advancing small molecule therapeutics to improve Alzheimer’s disease treatments by re-establishing lost connections between brain cells. M3 is now in the process of planning a first-in-humans Phase 1a clinical trial for its lead candidate, NDX-1017, to evaluate its safety and determine optimal dosing range.